ＢＡＫ療法(免疫療法)について

質問

知人が肺がん治療のため仙台にある、BAK免疫療法を受けようとしています。どのくらい効果が期待できるのか、経験されたかた、あるいは知り合いで受けたことのある人の経験など知っているかたがいましたら、お話をお聞かせください。

回答No.1

inoge · ベストアンサー

検索したらけっこうまともな雑誌にこんな記事を書いておられます
要約は英語ですが原文は日本語のはずです
大学の図書館に行けば読めると思います
もしくは雑誌（日本臨床　２００６年７月号）を取り寄せてみてください

1: Nippon Rinsho. 2006 Jul;64(7):1339-44.
Links
[Non-small cell lung cancer--immunocell BAK (BRM activated killer) therapy]
[Article in Japanese]
Ebina T.

The Sendai Institute for Microbiology, Immunotherapy Center.

We enrolled in this study 14 immunosuppressed non-small cell lung cancer (NSCLC) outpatients whose IAP level in serum were over 580 microg/ml and 26 immunoreactive outpatients whose IAP level in serum were under 580 microg/ml. After giving informed consent, patients were treated with BAK therapy on an outpatient basis. Treated with BAK therapy, the mean survival of immunosuppressed patients was 5.2 months, on the other hand, one of immunoreactive patients was 26.3 months. The difference in survival between 2 groups was significant (p<0.01). A stage IV NSCLC patient whose serum IAP is under 580 microg/ml is good indication for BAK therapy. The favorable clinical response in lung cancer patients to BAK treatment may be due to the fact that lungs are the first exposed to BAK cells via the blood stream. BAK therapy has a life prolonging effect with no apparent adverse effects for advanced NSCLC patients.

PMID: 16838654 [PubMed - indexed for MEDLINE]

参考URL：

http://www.nippon-rinsho.co.jp/

お礼

ありがとうございます。参考にさせていただきます。